BURLINGTON, Mass., April 10, 2014 /PRNewswire/ -- Decision Resources Group finds that the effect of a therapy on overall survival and progression-free survival are attributes that most influence surveyed U.S. and European hematological oncologists' prescribing decisions for relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In addition, U.S. and European hematological oncologists, as well as U.S. payers indicate that improving overall survival is one of the greatest unmet needs in R/R CLL/SLL. The novel mechanism of action of first-in-class kinase inhibitors ibrutinib (Johnson & Johnson/Janssen/Pharmacyclics' Imbruvica) and idelalisib (Gilead Sciences) has elicited great enthusiasm from interviewed experts. These experts perceive that ibrutinib and idelalisib offer a major advantage in efficacy compared with the current major-market sales and patient share leader, FCR*. It is expected that these agents will be added to rituximab-containing regimens, such as bendamustine (Teva Pharmaceutical Industries' Treanda, Mundipharma's Ribomustin/Levact, Symbio Pharmaceuticals/Eisai's Treakisym) in combination with rituximab, currently used in this difficult-to-treat patient population. Moreover, hematological oncologists express enthusiasm for Celgene's Revlimid, Roche/Genentech/Chugai/Glycart's Gazyva, and Roche/Genentech/AbbVie's ABT-199, with regard to their potential for overall survival improvement in this setting. 

* Fludarabine (Genzyme's Fludara, Bayer HealthCare's Fludara/Beneflur, generics) + cyclophosphamide (Bristol-Myers Squibb's Cytoxan, Pfizer's Cyclophospham, generics) + rituximab (Roche/Genentech/Chugai Seiyaku/Zenyaku Kogyo's Rituxan/MabThera)

Other key findings from the DecisionBase report entitled Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Relapsed/Refractory): As the Relapsed/Refractory Treatment Setting for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Becomes More Crowded, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers?: 

  • Bendamustine in combination with rituximab (BR): reflecting available clinical data and the opinions of interviewed thought leaders, our report indicates that the BR regimen is the current gold-standard therapy for treatment of R/R CLL/SLL.
  • Overall response rate: surveyed U.S. payers indicate that emerging therapies offering improvements in overall response rate over existing therapies are likely to be included on formularies.
  • Ibrutinib: surveyed U.S. hematological oncologists indicate that they would prescribe ibrutinib in combination with BR to 50 percent of their R/R CLL/SLL patients.

Comments from Decision Resources Group Analyst Dana Gheorghe, Ph.D.:

  • "The relapsed/refractory CLL/SLL setting is highly heterogenic, with age, fitness, performance status, cytogenetic profile, and time between the last treatment and disease progression all playing a role in the treatment algorithm; therapies such as FCR and BR have proven to be efficacious in this setting, but an improved overall survival remains an unmet need."
  • "Ibrutinib monotherapy is now FDA-approved for R/R CLL, and the drug continues to generate tremendous interest as a result of its proven efficacy; the ibrutinib/BR combination has the potential to offer overall survival and disease progression improvements in the relapsed/refractory CLL/SLL setting."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com 

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO  

SOURCE Decision Resources Group

U.S. Market for Pain Management Devices Will Reach Nearly $2.7 Billion by 2022

View Now